Seattle Genetics Inc. (NASDAQ:SGEN) Director Felix Baker bought 546,252 shares of the stock on the open market in a transaction dated Monday, June 9th. The shares were purchased at an average price of $38.16 per share, for a total transaction of $20,844,976.32. Following the transaction, the director now directly owns 76,997 shares in the company, valued at approximately $2,938,206. Seattle Genetics, Inc. (NASDAQ:SGEN) net profit margin is -22.30% and weekly performance is 12.84%. On last trading day company shares ended up $40.08. Analysts mean target price for the company is $45.15. Seattle Genetics, Inc. (NASDAQ:SGEN) distance from 50-day simple moving average (SMA50) is 6.95%.
Cytori Therapeutics Inc. (USA) (NASDAQ:CYTX) Director David Rickey acquired 30,000 shares of the company’s stock on the open market in a transaction that occurred on Thursday, June 5th. The shares were purchased at an average price of $2.34 per share, for a total transaction of $70,200.00. Following the acquisition, the director now directly owns 15,819 shares of the company’s stock, valued at approximately $37,016. Cytori Therapeutics Inc. (USA) (NASDAQ:CYTX) shares advanced 0.41% in last trading session and ended the day on $2.43. CYTX gross Margin is 68.70% and its return on assets is -73.90%.Cytori Therapeutics Inc. (USA) (NASDAQ:CYTX) quarterly performance is -20.85%.
Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP)’s Major Shareholder Regals Capital Management Lp buy 2,252 shares of ORMP in a transaction dated on June 6, 2014. Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) shares were purchased at an average price of $4.44 for total worth of $9,998.88.
Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) shares moved up 10.05% in last trading session and was closed at $9.09, while trading in range of $8.22 – $9.18. Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) year to date (YTD) performance is -41.09%.
TrovaGene Inc. (NASDAQ:TROV)’s CFO Steve Zaniboni buy 6,329 shares of TROV in a transaction dated on June 9, 2014. TrovaGene Inc. (NASDAQ:TROV) shares were purchased at an average price of $3.95 for total worth of $24,999.55. TrovaGene Inc. (NASDAQ:TROV) ended the last trading day at $3.88. Company weekly volatility is calculated as 6.88% and price to cash ratio as 2.84.TrovaGene Inc. (NASDAQ:TROV) showed a negative weekly performance of -0.51%.
Heat Biologics Inc. (NASDAQ:HTBX) Chief Executive Officer Jeff A. Wolf, MBA bought 346 shares in a transaction dated Monday, 19 may. The shares were purchased at an average price of $4.1 per share, with a total value of $1418.Heat Biologics Inc. (NASDAQ:HTBX) weekly performance is 0.68%. On last trading day company shares ended up $4.43. Analysts mean target price for the company is $20.00. Heat Biologics Inc. (NASDAQ:HTBX) distance from 50-day simple moving average (SMA50) is -13.09%.